SPIKE PROFIT: Profit in the first quarter of Merck & Co. has more than tripled on reducing the costs of the integration of Schering-Plough and double-digit growth in sales for essential drugs, compensate for competition from generic versions of two drugs big heart.
Numbers: Merck had adjusted profit of $ 2.86 billion, or 92 cents a share and revenue of 11.58 billion, beating Wall Street expectations.
BOOST MERCK: the just society has obtained the approval of a promising drug for melanoma, Sylatron and has five experimental drugs under review by us regulators and Europeans, including those for diabetes, hepatitis c and contraception.
No comments:
Post a Comment